Brain health, cognitive impairment and dementia — how to evaluate, manage and refer, including anti-amyloid therapy. Most patients need only 2–3 answers to find the right route.
Answer a few questions about your patient. You’ll get the order to place, who to copy, and a referral comment you can paste.
p-tau217 answers one question: is Alzheimer amyloid likely present? It does not diagnose dementia, stage disease, or explain every symptom.
VIP or expedite requests: route through the Neurocognitive triage pool so the same pathway is followed.
Often the single most helpful intervention. Treat it as an advisory review prompt, not a hard stop.
| Test | When | Practical notes |
|---|---|---|
| Vitamin B1 (thiamine) | Everyone | Part of the standard cognitive lab panel. |
| Vitamin B12 | Everyone | Neurocognitive practice supplements below 400 pg/mL in patients with cognitive symptoms. Read with MMA: low-normal B12 with elevated MMA supports functional deficiency. |
| Folate (vitamin B9) | Everyone | Especially relevant with malnutrition, alcohol use, malabsorption or macrocytosis. |
| Methylmalonic acid (MMA) | Everyone | Order with B12 — elevated MMA with low-normal B12 supports functional deficiency. |
| Homocysteine | Everyone | Interpret with B12, folate and MMA; vascular and nutritional confounders. |
| CBC | Everyone | Anemia and macrocytosis. Hemoglobin also matters for p-tau217 interpretation (anemia lowers its positive predictive value). |
| CMP | Everyone | Renal function (eGFR) for p-tau217 interpretation; sodium, glucose and liver function as reversible contributors. |
| TSH | Routine, about yearly | Repeat sooner with known thyroid disease, abnormal prior results, dose changes, or adherence concerns. |
| Syphilis serology (RPR) | Appropriate population | When history or risk factors suggest it. A 5-year lookback is reasonable; repeat sooner with new sexual history or risk. |
| Plasma p-tau217 (Mayo PT217) | MoCA 26 or below, or objective impairment, and AD is in the differential | Not more than yearly unless monitoring AAT. Do not order for memory concerns NOS, worried-well, or family members. An existing dementia diagnosis is not an exclusion if never biomarker-tested. |
| Plasma Aβ42/40, p-tau181 | Not for routine PCP use | Pre-analytic handling issues; keep the PCP pathway centered on p-tau217. |
An incomplete workup routes to other neurology resources first, which adds time.
| Lecanemab (Leqembi) | Donanemab (Kisunla) | |
|---|---|---|
| Target | Soluble Aβ protofibrils | Deposited plaque (N-terminal pyroglutamate Aβ) |
| Dosing | IV every 2 weeks, ongoing | IV every 4 weeks; may stop after plaque clearance |
| Efficacy (trials) | 27% slowing on CDR-SB at 18 months | About 35% slowing on iADRS in low/medium tau; 22–29% overall |
| ARIA-E (trial) | 12.6% | 24.0% standard; 15.6% modified titration |
| Surveillance MRI | Baseline, then before infusions 3, 5, 7, 14 | Baseline, then before infusions 2, 3, 4, 7 |
These drugs slow decline; they do not stop or reverse disease. Best responses occur with milder symptoms and lower tau burden.
| Situation | Action |
|---|---|
| Sudden confusion, new weakness or speech change, seizure | Emergency Department the same day. |
| Acute agitation or aggression the family cannot manage | Emergency Department; 911 for immediate danger. |
| Firearm in the home | Ask every visit. Remove, or lock away unloaded with ammunition separate and the key kept from the patient. Immediate danger: 911. |
| Suspected abuse, neglect, self-neglect, exploitation | Age 60+: Elderly Protective Services 1-833-577-6532 (weekdays 8:00–4:30), after hours 1-844-945-2377. Age 18–59: Adult Protective Services 1-800-898-4910 (24/7). Louisiana requires reporting. |
Nothing is saved or sent — it’s a scratch list for the visit you’re in.
Clinical guidance for Ochsner internal medicine and primary care clinicians, from the Ochsner Neurocognitive Program (November 2026). It supports — and does not replace — clinical judgment; final anti-amyloid eligibility is decided by the neurocognitive physician. See also the Ochsner Neurocognitive Program and Ochsner CAA Program.